Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $7.6667.

NMRA has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Tuesday, April 21st. Guggenheim reaffirmed a “buy” rating and set a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 31st. Finally, William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th.

Neumora Therapeutics Stock Up 7.6%

NMRA stock opened at $1.85 on Friday. The company has a quick ratio of 5.09, a current ratio of 5.09 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $342.77 million, a PE ratio of -1.39 and a beta of 3.02. Neumora Therapeutics has a twelve month low of $0.66 and a twelve month high of $3.65. The stock has a 50-day simple moving average of $2.23 and a two-hundred day simple moving average of $2.35.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. On average, equities analysts predict that Neumora Therapeutics will post -0.98 EPS for the current fiscal year.

Institutional Trading of Neumora Therapeutics

A number of large investors have recently modified their holdings of NMRA. Invesco Ltd. boosted its position in shares of Neumora Therapeutics by 151.1% during the 1st quarter. Invesco Ltd. now owns 123,655 shares of the company’s stock valued at $124,000 after acquiring an additional 74,406 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Neumora Therapeutics during the 1st quarter valued at about $463,000. Russell Investments Group Ltd. boosted its position in shares of Neumora Therapeutics by 2,898.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 73,812 shares of the company’s stock valued at $56,000 after acquiring an additional 71,350 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Neumora Therapeutics during the 2nd quarter valued at about $183,000. Finally, Federated Hermes Inc. boosted its position in shares of Neumora Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 314,119 shares of the company’s stock valued at $230,000 after acquiring an additional 29,543 shares during the last quarter. Institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.